Terms: = Prostate cancer AND RBM15, Q96T37, 64783, ENSG00000162775, OTT, OTT1 AND Treatment
8 results:
1. Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review.
Parikh S; Zhang Y; Sherwani Z; Kumar R; Ohri N; Jan I; Vergalasova I; Jabbour S; Hathout L
Brachytherapy; 2024; 23(2):141-148. PubMed ID: 38307787
[TBL] [Abstract] [Full Text] [Related]
2. From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial.
De Cock L; Draulans C; Pos FJ; Isebaert S; De Roover R; van der Heide UA; Smeenk RJ; Kunze-Busch M; van der Voort van Zyp J; de Boer H; Kerkmeijer LGW; Haustermans K
Radiother Oncol; 2023 Aug; 185():109713. PubMed ID: 37178932
[TBL] [Abstract] [Full Text] [Related]
3. Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial Exploring Optimal Sequencing of Short-Term Androgen Deprivation Therapy With prostate Radiation Therapy in Localized prostate cancer.
Roy S; Grimes S; Morgan SC; Eapen L; Malone J; Craig J; Spratt DE; Malone S
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1101-1113. PubMed ID: 33524545
[TBL] [Abstract] [Full Text] [Related]
4. Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter?
Achard V; Jorcano S; Rouzaud M; Escudé L; Miralbell R; Zilli T
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1581-1588. PubMed ID: 30887155
[TBL] [Abstract] [Full Text] [Related]
5. Management of interruptions to fractionated radiotherapy treatments: Four and a half years of experience.
de la Vega JM; Ríos B; Del Río JT; Guerrero R; Castillo I; Guirado D
Phys Med; 2016 Dec; 32(12):1551-1558. PubMed ID: 27890566
[TBL] [Abstract] [Full Text] [Related]
6. Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for prostate cancer: Do Dose and Overall treatment Time Matter?
Kountouri M; Zilli T; Rouzaud M; Dubouloz A; Linero D; Escudé L; Jorcano S; Miralbell R
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):272-9. PubMed ID: 26853336
[TBL] [Abstract] [Full Text] [Related]
7. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.
Tunn UW; Canepa G; Kochanowsky A; Kienle E
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):296-302. PubMed ID: 22733160
[TBL] [Abstract] [Full Text] [Related]
8. Comparison of traditional and simultaneous IMRT boost technique basing on therapeutic gain calculation.
Slosarek K; Zajusz A; Szlag M
Med Dosim; 2008; 33(4):299-302. PubMed ID: 18973858
[TBL] [Abstract] [Full Text] [Related]
